Efficacy and safety of extended-interval dosing of natalizumab in multiple sclerosis: a systematic review and meta-analysis with subgroup evaluation.

Hammadeh BM, Sameer S, Alnajjar M, Abu-Issa I, Alhallaq MS, Ghazi M, Badr A, Shawawrah M

Neurol Sci. 2026 Jul 03; 47(8). PMID: 42393408. Abstract